Products
Platform
Research
Market
Learn
Compare Nippon India Pharma Fund vs ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Fund Details
Risk | Very High | Very High |
Rating | 3.0 | 5.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 1.82 | 1.87 |
NAV | ₹512.75 | ₹40.33 |
Fund Started | 10 May 2004 | 25 Jun 2018 |
Fund Size | ₹8113.59 Cr | ₹6226.82 Cr |
Exit Load | Exit load of 1% if redeemed within 1 month. | Exit load of 1% if redeemed within 15 days. |
Risk
Very High
Very High
Rating
3.0
5.0
Min SIP Amount
₹100
₹100
Expense Ratio
1.82
1.87
NAV
₹512.75
₹40.33
Fund Started
10 May 2004
25 Jun 2018
Fund Size
₹8113.59 Cr
₹6226.82 Cr
Exit Load
Exit load of 1% if redeemed within 1 month.
Exit load of 1% if redeemed within 15 days.
Returns
1 Year | -2.76% | 2.62% |
3 Year | 21.91% | 28.00% |
5 Year | 17.40% | 20.28% |
1 Year
-2.76%
2.62%
3 Year
21.91%
28.00%
5 Year
17.40%
20.28%
Holding Analysis
Equity | 99.44% | 97.55% |
Cash | 0.56% | 2.45% |
Equity
99.44%
97.55%
Cash
0.56%
2.45%
Top Holdings
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 12.29% |
Lupin Ltd. | 7.26% |
Divi's Laboratories Ltd. | 7.01% |
Cipla Ltd. | 6.48% |
Apollo Hospitals Enterprise Ltd. | 5.92% |
Dr. Reddy's Laboratories Ltd. | 5.91% |
Vijaya Diagnostic Centre Ltd. | 3.56% |
Medplus Health Services Ltd. | 3.39% |
Gland Pharma Ltd. | 3.24% |
Glaxosmithkline Pharmaceuticals Ltd. | 2.99% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 11.58% |
Dr. Reddy's Laboratories Ltd. | 9.10% |
Divi's Laboratories Ltd. | 8.75% |
Aurobindo Pharma Ltd. | 8.25% |
Cipla Ltd. | 6.92% |
Lupin Ltd. | 5.43% |
Alkem Laboratories Ltd. | 4.05% |
Biocon Ltd. | 3.11% |
Gland Pharma Ltd. | 2.97% |
Mankind Pharma Ltd. | 2.95% |
Fund Manager
Name | Akshay Sharma | Dharmesh Kakkad |
Start Date | 01 Dec 2022 | 23 Feb 2021 |
Name
Akshay Sharma
Dharmesh Kakkad
Start Date
01 Dec 2022
23 Feb 2021
About Fund
Description | The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 10 May 2004 | 25 Jun 2018 |
Description
The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Launch Date
10 May 2004
25 Jun 2018